文献速递心境障碍

斯坦福神经调控疗法(SNT)双盲随机对照试验

Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial.
PubMed 文献 · Am J Psychiatry · 2021-10-29

该双盲假对照试验纳入难治性抑郁症患者,采用功能连接引导靶向的高剂量间歇性θ爆发刺激方案(SNT)。治疗4周后,活性组MADRS评分较基线平均降低52.5%,假刺激组降低11.1%,表明SNT优于假刺激。

要点

  • SNT为功能连接引导靶向的高剂量iTBS加速方案。
  • 4周后MADRS较基线平均降低:活性组52.5%,假组11.1%。
  • SNT对难治性抑郁症疗效优于假刺激,需进一步验证耐久性。

核心结论

  • SNT是一种功能连接引导靶向的高剂量iTBS方案,对难治性抑郁症的疗效优于假刺激。

研究设计与样本

  • 双盲假对照随机对照试验,纳入32例难治性抑郁症患者,29例继续符合标准者接受活性(N=14)或假(N=15)SNT。

主要发现

  • 治疗4周后MADRS评分较基线平均降低百分比:活性组52.5%,假刺激组11.1%。

关键数值与推荐

  • 主要结局为治疗4周后MADRS评分。
  • 靶区为左侧背外侧前额叶皮层中与膝下前扣带回皮层功能最负相关的区域,由静息态fMRI个体化定位。

临床怎么用

  • SNT可作为难治性抑郁症的候选神经调控治疗,需个体化功能连接靶向并采用高剂量iTBS加速方案。

局限性

  • 原文指出需进一步试验确定SNT的耐久性并与其他治疗比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Depression is the leading cause of disability worldwide, and half of patients with depression have treatment-resistant depression. Intermittent theta-burst stimulation (iTBS) is approved by the U.S. Food and Drug Administration for the treatment of treatment-resistant depression but is limited by suboptimal efficacy and a 6-week duration. The authors addressed these limitations by developing a neuroscience-informed accelerated iTBS protocol, Stanford neuromodulation therapy (SNT; previously referred to as Stanford accelerated intelligent neuromodulation therapy, or SAINT). This protocol was associated with a remission rate of ∼90% after 5 days of open-label treatment. Here, the authors report the results of a sham-controlled double-blind trial of SNT for treatment-resistant depression. METHODS: Participants with treatment-resistant depression currently experiencing moderate to severe depressive episodes were randomly assigned to receive active or sham SNT. Resting-state functional MRI was used to individually target the region of the left dorsolateral prefrontal cortex most functionally anticorrelated with the subgenual anterior cingulate cortex. The primary outcome was score on the Montgomery-Åsberg Depression Rating Scale (MADRS) 4 weeks after treatment. RESULTS: At the planned interim analysis, 32 participants with treatment-resistant depression had been enrolled, and 29 participants who continued to meet inclusion criteria received either active (N=14) or sham (N=15) SNT. The mean percent reduction from baseline in MADRS score 4 weeks after treatment was 52.5% in the active treatment group and 11.1% in the sham treatment group. CONCLUSIONS: SNT, a high-dose iTBS protocol with functional-connectivity-guided targeting, was more effective than sham stimulation for treatment-resistant depression. Further trials are needed to determine SNT's durability and to compare it with other treatments.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Cole EJ, Phillips AL, Bentzley BS, et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. Am J Psychiatry. 2021. PMID: 34711062. doi:10.1176/appi.ajp.2021.20101429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。